National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2019 (No. 8) (PB 68 of 2019) (Cth)
PB 68 of 2019
National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2019 (No. 8)
National Health Act 1953
___________________________________________________________________________
I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.
Dated 29 August 2019
THEA DANIEL
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
___________________________________________________________________________
Name of Instrument
(1)This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2019 (No. 8).
(2)This Instrument may also be cited as PB 68 of 2019.
Commencement
This Instrument commences on 1 September 2019.
Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)
Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).
Schedule 1 Amendments
Schedule 1, after entry for Brivaracetam in the form Tablet 100 mg
insert:
| Buprenorphine | Injection (modified release) 8 mg in 0.16 mL pre-filled syringe | 20 | 1 | 0 |
| Injection (modified release) 16 mg in 0.32 mL pre-filled syringe | 20 | 1 | 0 | |
| Injection (modified release) 24 mg in 0.48 mL pre-filled syringe | 20 | 1 | 0 | |
| Injection (modified release) 32 mg in 0.64 mL pre-filled syringe | 20 | 1 | 0 | |
| Injection (modified release) 64 mg in 0.18 mL pre-filled syringe | 20 | 1 | 0 | |
| Injection (modified release) 96 mg in 0.27 mL pre-filled syringe | 20 | 1 | 0 | |
| Injection (modified release) 128 mg in 0.36 mL pre-filled syringe | 20 | 1 | 0 |
Schedule 1, entry for Esomeprazole in the form Capsule (enteric) 20 mg (as magnesium)
insert as first entry:
| 20 | 30 | 1 |
Schedule 1, entry for Esomeprazole in the form Capsule (enteric) 40 mg (as magnesium)
insert as first entry:
| 20 | 30 | 1 |
Schedule 1, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium trihydrate)
insert as first entry:
| 20 | 30 | 1 |
Schedule 1, entry for Esomeprazole in the form Tablet (enteric coated) 40 mg (as magnesium trihydrate)
insert as first entry:
| 20 | 30 | 1 |
Schedule 1, omit entry for Hydrochlorothiazide with triamterene
Schedule 1, entry for Insulin isophane
omit:
| Injection (bovine) 100 units per mL, 10 mL | 20 | 5 | 2 |
Schedule 1, entry for Insulin neutral
omit:
| Injection (bovine) 100 units per mL, 10 mL | 20 | 5 | 2 |
Schedule 1, entry for Lansoprazole in the form Capsule 30 mg
insert as first entry:
| 20 | 28 | 1 |
Schedule 1, entry for Lansoprazole in the form Tablet 30 mg (orally disintegrating)
insert as first entry:
| 20 | 28 | 1 |
Schedule 1, entry for Omeprazole in the form Capsule 20 mg
insert as first entry:
| 20 | 30 | 1 |
Schedule 1, entry for Omeprazole in the form Tablet 20 mg
insert as first entry:
| 20 | 30 | 1 |
Schedule 1, entry for Omeprazole in the form Tablet 20 mg (as magnesium)
insert as first entry:
| 20 | 30 | 1 |
Schedule 1, entry for Pantoprazole in the form Sachet containing granules 40 mg (as sodium sesquihydrate)
insert as first entry:
| 20 | 30 | 1 |
Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate)
insert as first entry:
| 20 | 30 | 1 |
Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated)
insert as first entry:
| 20 | 30 | 1 |
Schedule 1, entry for Ribavirin
omit:
| Tablet 200 mg | 20 | 28 | 5 |
0
0
0